Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies
Chimeric antigen receptor (CAR) therapy targeted against CD19 has yielded remarkable clinical responses in the treatment of relapsed/refractory B-cell malignancies, but about a third of patients ultimately relapse due to the loss or downregulation of CD19. Furthermore, technical and logistical challenges associated with autologous CAR T therapy limits access for a majority of eligible patients. To help address these challenges, we have developed an allogeneic bispecific tandem CAR directed against both CD19 and CD20 (ATA3431) built on our Epstein –Barr virus (EBV) T-cell platform. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Seung Cha, Morgan Charbonneau, Alfonso Brito, Ania Habibi, Christina Pham, Cokey Nguyen Tags: 13 Source Type: research

Chimeric Antigen Receptor Design in Human Mesenchymal Stromal Cells (CAR-MSCs) Mediates Homing to Target Sites and Downstream Immunosuppression for Immune Disease Treatment
Allogeneic mesenchymal stromal cell (MSC) therapy for immune disease is generally safe but often ineffective in clinical trials, in part due to poor trafficking and limited immunosuppression. To overcome these obstacles, we have created novel chimeric antigen receptor (CAR)-MSCs. We hypothesized that CAR-MSCs would show superior 1) homing to target tissues due to a tissue-specific antigen binding domain and 2) immunosuppression due to inclusion of immunosuppressive intracellular signaling domains. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Olivia Sirpilla, R. Leo Sakemura, Mehrdad Hefazi, Brooke L Kimball, Truc N Huynh, Elizabeth L. Siegler, Saad S. Kenderian Tags: 14 Source Type: research

Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT
Leukemia recurrence is the most common type of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT) for pediatric AML. We have advanced memory-like (ML) NK cells as a cellular therapy for AML. NK cells differentiated to ML NK cells after stimulation with interleukins-12, -15, and -18 display significantly enhanced anti-leukemia functionality and in vivo persistence. We performed a prospective clinical trial utilizing donor lymphocyte (DLI) and ML NK cell infusions to treat relapsed AML after allo-HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Thomas Pfeiffer, Clare Zimmerman, Melissa M Berrien-Elliott, Jennifer Foltz, Michelle Becker-Hapak, Carly Neal, Mark Foster, Timothy Schappe, Ethan McClain, Patrick Pence, Sweta Desai, Pamela Wong, David Russler-Germain, Bryan Fisk, Lie Wen-Rong, Jeremy E Tags: 15 Source Type: research

Enhanced Immune Reconstitution and Reduced GvHD Risk with T-allo10 Infusion Post A βdepleted-HSCT in Pediatric and Young Adult Patients with Hematologic Malignancies
Allogeneic hematopoietic stem cell transplantation (HSCT) has been historically hindered by the scarcity of HLA-matched donors. TCR αβ+ T-cell and CD19+ B-cell-depleted (αβdepleted) HSCT has expanded the utilization of HLA-mismatched donors by reducing the incidence of severe graft-versus-host disease (GvHD). However, αβdepleted-HSCT still presents challenges such as viral reactivations (∼50%) and leukemic relapse (25-30 %) due to suboptimal immune reconstitution (IR).To address these hurdles, we combined αβdepleted-HSCT with a newly developed T-cell immunotherapy known as T-allo10. (Source: Biology of Blood and ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alice Bertaina, Rosa Bacchetta, David C. Shyr, Gopin Saini, Jennifer Lee, Karen Kristovich, Rajni Agarwal-Hashmi, Dr. Orly R. Klein, Kathryn Melsop, Keri Tate, Giulia Barbarito, Linda Oppizzi, Pauline Chen, Matthew H. Porteus, Alma-Martina Cepika, Maria G Tags: 16 Source Type: research

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001
We report outcomes from prespecified subgroup analyses based on high-risk features from the MCL cohort of TRANSCEND NHL 001 (NCT02631044) of liso-cel in pts with R/R MCL. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: M. Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Tags: 17 Source Type: research

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)
T-ALL/LBL are challenging hematologic cancers with high rates of relapse and mortality. WU-CART-007 is a CD7-targeted CAR-T cell product with CRISPR/Cas9 deletion of CD7 and T-cell receptor alpha constant (TRAC), to prevent fratricide and enable the use of allogeneic T-cells, respectively (Leedom et al. ASH 2021). This off-the-shelf allogeneic CAR-T cell product is being developed for the treatment of R/R T-ALL/LBL in an ongoing global first-in-human, Phase 1/2 single-agent study (NCT04984356).The RP2D of WU-CART-007 is 900 million (M) cells administered on day 1 following lymphodepleting chemotherapy (LDC). (Source: Biolo...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Dr. Dholaria Bhagirathbhai, Rawan G Faramand, Ryan J. Mattison, Michael P. Rettig, Kenneth Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Angela Pannunzio, Tags: 18 Source Type: research

Administration of Human Milk Oligosaccharide (2 ′-fucosyllactose) Reduces Dysbiosis and Increases Short Chain Fatty Acids in Children and Young Adults Following HSCT: A Prospective, Single-Center Study
Gut dysbiosis is implicated in the pathophysiology of graft-versus-host disease (GVHD). We have previously shown that human milk administration favorably modifies the gut microbiome and metabolome by virtue of human milk oligosaccharides (HMOs) that are known prebiotics (Khandelwal et al, 2019). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Kristie N. Ramos, Kelly E. Lake, Colin Hoerth, Lucille Langenberg, Nathan Luebbering, David Haslam, David Newburg, Ardythe L Morrow, Nicholas J. Ollberding, Lee A Denson, Miki Watanabe-Chailland, Lindsey Romick-Rosendale, Stella M. Davies, Pooja Khandelwa Tags: 19 Source Type: research

Age, Gvhd Prophylaxis, and Timing Matter in Thrombotic Microangiopathy after Hematopoietic Cell Transplantation- a Secondary CIBMTR Analysis
Hematopoietic cell transplantation associated thrombotic microangiopathy (TA-TMA) is associated with significant morbidity and mortality. Risk factors for developing TA-TMA and impact of TA-TMA on survival were published from a large Center for International Blood and Marrow Transplant Research (CIBMTR) (Epperla et al, BJH. 2020). We used this database to investigate whether there were different risk factors (RF) for developing TA-TMA in children and adults and identify prognostic factors, including timing of TA-TMA diagnosis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Michelle Long Schoettler, Benjamin K. Watkins, Muna Qayed, Satheesh Chonat, Adrianna Lynn Westbrook, Kirsten Williams Tags: 20 Source Type: research

Ceramides Are Elevated in Transplant-Associated Thrombotic Microangiopathy in Hematopoietic Stem Cell Transplant Recipients and Are a Druggable Target for Prophylaxis.
Ceramides (Cer) are sphingolipids critical to maintaining endothelial barrier homeostasis and integrity. Ceramides cause oxidative stress in human endothelial cells, thereby reducing levels of bioactive nitric oxide (NO). NO inhibits platelet aggregation, prevents adhesion of platelets to the endothelial surface and induces disaggregation of aggregating platelets. We hypothesized that disruption of ceramides contributes to the etiology of TA-TMA and that ceramides represent a target for prophylaxis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jane Koo, Lucille Langenberg, Nathan Luebbering, Lauren Strecker, Sheyar Abdullah, Elizabeth Carusone, Marisa Deavy, Colin Hoerth, Gillian Miller, Deena Turner, Kelly E. Lake, Kenneth Setchell, Wujuan Zhang, Xueheng Zhao, Assem G. Ziady, Kasiani C Myers, Tags: 21 Source Type: research

Effects of Palliative Care on Quality of Life and Psychological Distress of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) and Their Caregivers
Patients undergoing HSCT and their caregivers endure substantial psychological distress during the transplant hospitalization. Prior single-center studies established the feasibility and promising efficacy of integrating palliative care during the HSCT hospitalization. However, data regarding the efficacy of this care model across diverse care settings are lacking. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Areej R. El-Jawahri, Thomas LeBlanc, Ali Rhodes Kavanaugh, Jason A Webb, James Fausto, Lara Traeger, Joseph A. Greer, Vicki Jackson, Nora Horick, Dustin Rabideau, Zachariah DeFilipp, Dr. Yi-Bin Chen, Stephanie J Lee, Jennifer Temel Tags: 22 Source Type: research

Novel Implementation of Photobiomodulation Therapy Decreases Oral Mucositis Severity in Pediatric Stem Cell Transplant (SCT) Patients
Oral mucositis (OM) is a common acute SCT complication affecting up to 90% of pediatric patients undergoing SCT. OM consists of painful ulcerations in the oral cavity and throat that interfere with dietary intake and oral care compliance. Patients with high-grade OM require patient-controlled analgesia (PCA), total parenteral nutrition (TPN) and intravenous (IV) medications thus increasing length of stay (LOS) and hospital costs. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sharon Staton, Kathleen Magee, Jenell Robins, Andrea Davis, Corina Coffman, Abigail Koehn, Gabriela Llaurador Tags: 23 Source Type: research

TA-TMA Is Frequent, but Not All TA-TMA Is Actionable in Adult Allogeneic HCT Patients: A Report from the MIDAS (Microangiopathy, Endothelial Damage in Adults undergoing Stem cell transplantation) Consortium.
Transplant-associated thrombotic microangiopathy (TA-TMA) can be associated with significant morbidity and mortality but is under-studied in adults. An expert consensus panel recently published Modified Jodele Criteria (MJC) to define TA-TMA with the intent for adoption across transplant registries and centers (PMID: 36442770).We performed the first study in adults applying MJC criteria for TA-TMA in a prospective cohort with weekly biospecimen and data collection through day+100 after allogeneic HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sumithira Vasu, Nelli Bejanyan, Elizabeth Greer Miller, Patrick Elder, Qiuhong Zhao, Stella M. Davies, Theresa E. Hahn Tags: 24 Source Type: research

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
Limitations of effective CD19-targeted chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory (R/R) B-cell lymphoma (BCL) include lack of sustained remissions and the potential for adverse effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). BTK inhibitors are immunomodulatory and may enhance CAR T-cell expansion, engraftment and tumor clearance while decreasing the frequency and severity of CRS (Gauthier, et al. Blood 2020). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Edus H Warren, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Jordan Gauthier, Alexandre V Hirayama, Stephen D Smith, Taran Gujral, Chihiro Morishima, Vicky Wu, Jenna M Voutsinas, Joshua Diz Tags: 37 Source Type: research

Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
An unmet need exists for effective, well-tolerated, and convenient treatment (tx) options in patients (pts) with high-risk relapsed/refractory (R/R) follicular lymphoma (FL), including double refractory pts (refractory to anti-CD20 tx and an alkylating agent) and pts with disease progression within 2 y of first-line (1L) immunochemotherapy (POD24). Epcoritamab, a subcutaneous (SC) CD3xCD20 bispecific antibody, is approved in the US for adults with R/R diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic tx...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Kim M Linton, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Herve Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Umberto Vitolo, Tara Cochrane, Tags: 38 Source Type: research

Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.
Outcomes after CART cell therapy in myeloma is not well known in the literature and the question of whether subsequent immune engager therapies (IET) are efficacious due to T cell exhaustion also remain. Hence, we examined the outcomes of patients post ide-cel, and characterized relapses, therapies, and Progression free survival (PFS) PFS-1, PFS-2 in a real-world setting.Methods: This was a retrospective multicenter observational study of patients who underwent treatment for relapsed Multiple myeloma (MM) with ide-cel from 11 US medical centers. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Murali Janakiram, Jack Khouri, Omar Castaneda, Leyla Shune, Danai Dima, Gurbakhash Kaur, Gabe De Avila, Mahmoud Gaballa, Shonali Midha, James Davis, Charlotte Wagner, Joseph P McGuirk, Peter Forsberg, Ran Reshef, Yi Lin, Aimaz Afrough, Larry D. Anderson, Tags: 39 Source Type: research